文献速递神经肿瘤

加拿大安大略省胶质母细胞瘤(世界卫生组织4级胶质瘤)的人群队列研究:25年来诊疗持续改善

A Population-Based Cohort Study of Glioblastoma (World Health Organization Grade 4 Gliomas) in Ontario: Continued Improvement in Care over 25 Years.
PubMed 文献 · World Neurosurg · 2025-02-21

该研究基于安大略省行政健康数据,纳入1994至2018年9487例成人胶质母细胞瘤患者,比较不同时期、年龄组和中心的治疗与生存。中位生存期从6.4个月升至9.4个月,2年生存率从10%升至18%,住院时间减少8.9天,但区域中心间管理与结局存在显著异质性。

要点

  • 中位生存期从6.4个月升至9.4个月,2年生存率从10%升至18%。
  • 住院时间研究期间减少8.9天(95%CI 8.53-9.25)。
  • 区域治疗中心间患者管理与结局存在显著异质性。

核心结论

  • 4级胶质瘤的真实世界预后仍然很差,但接受最大程度治疗的患者比例增加与生存小幅但有意义的改善及住院时间减少相关,最老年患者除外。

研究设计与样本

  • 基于加拿大安大略省行政健康数据的单支付方省级人群队列研究,纳入1994至2018年9487例成人(>18岁)经病理或临床诊断的胶质母细胞瘤患者,随访至死亡或2年研究终点。

主要发现

  • 中位生存期从6.4个月改善至9.4个月,2年生存率从10%改善至18%。
  • 年龄较大与更短生存相关(65-74岁中位生存12个月 vs >85岁3个月),治疗强度更低,住院时间占余生比例更高(>75岁患者中超过三分之一将≥50%的剩余生存时间用于住院)。
  • 研究期间住院时间减少8.9天(95%CI 8.53-9.25)。
  • 区域治疗中心间患者管理与结局存在显著异质性。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Grade 4 glioma is the most common and fatal primary malignant brain tumor in adults. We sought to describe the evolution of care and survival of patients with glioblastoma in a single-payer Canadian provincial health care system over a 24-year period. METHODS: Adult patients >18 years old with pathologically or clinically diagnosed glioblastoma (based on fourth or earlier edition of World Health Organization classification) in Ontario between 1994 and 2018 were identified and followed until death or study end point of 2 years through provincial administrative health data. Patient characteristics, type of treatment, survival, and time spent in the hospital were compared across time periods, age groups, and centers. RESULTS: We included 9487 patients with glioblastoma treated from 1994 to 2018. Median survival and 2-year survival rate improved over the study period from 6.4 to 9.4 months and 10% to 18%, respectively. Older age was associated with shorter survival (median survival of 12 months at 65-74 years vs. 3 months at > 85 years), less aggressive therapy, and a higher proportion of remaining lifetime spent in the hospital (more than one third of patients >75 years spend ≥50% their remaining survival in hospital). Time in the hospital decreased by 8.9 days (95% confidence interval 8.53-9.25) over the study period. Significant heterogeneity exists in patient management and outcome between regional treatment centers. CONCLUSIONS: The real-world prognosis for grade 4 glioma remains poor. However, an increased proportion of patients receiving maximal therapy is associated with a small but meaningful improvement in survival and decreased time in the hospital for all but the oldest patients.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Taslimi S, Brogly S, Hanna TP, et al. A Population-Based Cohort Study of Glioblastoma (World Health Organization Grade 4 Gliomas) in Ontario: Continued Improvement in Care over 25 Years. World Neurosurg. 2025. PMID: 39987972. doi:10.1016/j.wneu.2025.123821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。